INCY

Incyte Corp
D

INCY

62.500
USD
0.50
(0.81%)
مغلق
حجم التداول
59,767
الربح لكل سهم
6
العائد الربحي
-
P/E
313
حجم السوق
12,098,120,875
أصول ذات صلة
ABBV
ABBV
5.160
(2.67%)
198.440 USD
A
AGIO
-0.850
(-2.75%)
30.060 USD
B
BLUE
-0.15000
(-3.69%)
3.91000 USD
BMY
BMY
1.000
(2.02%)
50.560 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
المزيد
الأخبار المقالات

العنوان: Incyte Corp

القطاع: Healthcare
الصناعة: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.